Total Score: 74/100
| Dimension | Score |
|---|---|
| Novelty | 8 |
| Mechanistic Rationale | 8 |
| Root Cause Coverage | 7 |
| Delivery Feasibility | 7 |
| Safety Plausibility | 7 |
| Combinability | 8 |
| Biomarker Availability | 7 |
| De-risking Path | 7 |
| Multi-disease Potential | 8 |
| Patient Impact | 7 |
| Disease | Coverage Score (1-10) |
|---|---|
| Alzheimer's Disease (AD) | 9 |
| Parkinson's Disease (PD) | 7 |
| Vascular Dementia (VaD) | 10 |
| Cerebral Amyloid Angiopathy (CAA) | 10 |
| Aging | 8 |
| FTD | 6 |
| DLB | 5 |
Delivery Innovation / Neuroimmune Modulation
Perivascular macrophages (PvMs) are CNS border-associated macrophages (BAMs) that reside in the perivascular space alongside cerebral blood vessels. These cells play critical roles in:
In neurodegenerative diseases, PvM function declines, contributing to accumulation of toxic proteins (Aβ, tau, α-syn) and impaired neurovascular coupling.
Enhanced Perivascular Clearance: PvMs are key effectors of perivascular waste drainage. Boosting their phagocytic activity can enhance clearance of Aβ, tau oligomers, and other toxic metabolites.
Immune Modulation: PvMs produce anti-inflammatory cytokines (IL-10, TGF-β) that can be enhanced to reduce neuroinflammation without compromising host defense.
Vascular Health: PvMs regulate endothelial health and pericyte function. Therapeutic modulation can improve cerebral blood flow and neurovascular coupling.
Disease Modification: By enhancing waste clearance and reducing neuroinflammation at the vascular interface, this approach targets two root causes simultaneously.
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Immune suppression | Low | Moderate | Local delivery, controlled dosing |
| Off-target inflammation | Low | Moderate | Targeted promoters |
| Insufficient delivery | Medium | High | Combination with BBB modulators |